trial

Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients With Schizophrenia

NCTId NCT05168007
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Unknown
Enrollment 342 (estimated)
Sponsored by Whanin Pharmaceutical Company
Primary completion 2023-07-17
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Unknown
Enrollment
342 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2021-11-19
Primary completion
2023-07-17
Eligibility
ALL · 19 Years · 64 Years

Interventions & indications

Drugs
Cariprazine (Vraylar)

Sponsors

Whanin Pharmaceutical CompanyLead Sponsor

Sites

1 total
Seoul, South Korea

Linked catalysts

1
Study Evaluating the Efficacy and Safety of WID-RGC20(Cariprazine) in Patients W — primary completion2023-07-17

Facts & assertions

4 sourced
Enrollment
342
Phase
PHASE3
Primary Completion Date
2023-07-17
Status
UNKNOWN
relationships
The graph out of here
drug
Cariprazine (Vraylar)
drug
lead_sponsor
Whanin Pharmaceutical Company
company
indication
Schizophrenia
indication
Schizophrenia
indication